Rigel acquires FDA-approved breast cancer drug VEPPANU for $70M upfront plus milestones

Filed May 12, 2026 · Period ending May 11, 2026 · ~1 min read

Key Changes

• high

  Rigel acquired exclusive worldwide rights to VEPPANU (vepdegestrant), an FDA-approved treatment for ER+, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, giving the company an immediate commercial-stage oncology asset.

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
• high

  The company will pay $70M upfront plus $15M upon transition completion, totaling $85M in near-term cash obligations, with up to $40M additional for development cost reimbursement during transition.

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
• high

  Rigel faces up to $320M in contingent milestones ($60M regulatory, $260M sales-based) plus tiered royalties of mid-teens to mid-twenties percentages on net sales, which will significantly impact product margins.

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →